IL-2 pathway blocking in combination with anti-CD154 synergistically establishes mixed macrochimerism with limited dose of bone marrow cells and prolongs skin graft survival in mice

Journal of Korean Medical Science

Volumn 21, Issue 6, 2006, Pages 1005-1011

  Lee, Jeong Hoon ^a   Ha, Jongwon ^b,c   Kim, Shi Hwa ^b,c   Sang, Joon Kim ^b,c  

^a Hallym University   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Abatacept; ABI1793 monoclonal antibody; Anti IL 2R; Asnti CD154; Bone marrow transplantation; Busulfan; CTLA4 Ig; Mixed chimerism; Skin transplantation; Transplantation chimera

Indexed keywords

EID: 33845898897     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2006.21.6.1005     Document Type: Article

References (34)

1. Rossini AA, Greiner DL, Mordes JP. Induction of immunologic tolerance for transplantation. Physiol Rev 1999; 79: 99-141.
2. Uchida N, Shirasugi N, Akiyama Y, Matsumoto K, Shimazu M, Kitajima M, Hamano K, Aramaki O, Ikeda Y, Niimi M. Induction of indefinite survival of fully allogeneic cardiac grafts and generation of regulatory cells by intratracheal delivery of alloantigens under blockade of the CD40 pathway. Transplantation 2003; 75: 878-84.
3. Graca L, Honey K, Adams E, Cobbold SP, Waldmann H. Cutting Edge: Anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. J Immunol 2000; 165: 4783-6.
4. Niimi M, Pearson TC, Larsen CP, Alexander DZ, Hollenbaugh D, Aruffo A, Linsley PS, Thomas E, Campbell K, Fanslow WC, Geha RS, Morris PJ, Wood KJ. The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo. J Immunol 1998; 161: 5331-7.
5. Kenyon NS, Fernandez LA, Lehmann R, Masetti M, Ranuncoli A, Chatzipetrou M, Iaria G, Han D, Wagner JL, Ruiz P, Berho M, Inverardi L, Alejandro R, Mintz DH, Kirk AD, Harlan DM, Burkly LC, Ricordi C. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 1999; 48: 1473-81.
6. Elster EA, Xu H, Tadaki DK, Burkly LC, Berning JD, Baumgartner RE, Cruzata F, Patterson NB, Harlan DM, Kirk AD. Primate skin allotransplantation with anti-CD154 monotherapy. Transplant Proc 2001; 33: 675-6.
7. Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner JH Jr, Germond RL, Kampen RL, Patterson NB, Swanson SJ, Tadaki DK, TenHoor CN, White L, Knechtle SJ, Harlan DM. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686-93.
8. Sayegh MH, Zheng XG, Magee C, Hancock WW, Turka LA. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation 1997; 64: 1646-50.
9. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994; 57: 1701-6.
10. Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181: 1869-74.
11. Jones TR, Ha J, Williams MA, Adams AB, Durham MM, Rees PA, Cowan SR, Pearson TC, Larsen CP. The role of the IL-2 pathway in costimulation blockade-resistant rejection of allografts. J Immunol 2002; 168: 1123-30.
12. Trambley J, Bingaman AW, Lin A, Elwood ET, Waitze SY, Ha J, Durham MM, Corbascio M, Cowan SR, Pearson TC, Larsen CP. Asialo GM1+ CD8+ T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999; 104: 1715-22.
13. Guo Z, Meng L, Kim O, Wang J, Hart J, He G, Alegre ML, Thistlethwaite JR Jr, Pearson TC, Larsen CP, Newell KA. CD8 T cell-mediated rejection of intestinal allografts is resistant to inhibition of the CD40/CD154 cotimulatory pathway. Transplantation 2001; 71: 1351-4.
14. Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Ythier A, Strom TB. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med 1985; 162: 358-62.
15. Kupiec-Weglinski JW, Diamantstein T, Tilney NL, Strom TB. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci USA 1986; 83: 2624-7.
16. Reed MH, Shapiro ME, Strom TB, Milford EL, Carpenter CB, Weinberg DS, Reimann KA, Letvin NL, Waldmann TA, Kirkman RL. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. Transplantation 1989; 47: 55-9.
17. MacLean JA, Su Z, Guo Y, Sy MS, Colvin RB, Wong JT. Anti-CD3: anti-IL-2 receptor bispecific monoclonal antibody. Targeting of activated T cells in vitro. J Immunol 1993; 150: 1619-28.
18. Nakamura T, Good RA, Yasumizu R, Inoue S, Oo MM, Hamashima Y, Ikehara S. Successful liver allografts in mice by combination with allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 1986; 83: 4529-32.
19. Ikehara S, Ohtsuki H, Good RA, Asamoto H, Nakamura T, Sekita K, Muso E, Tochino Y, Ida T, Kuzuya H, Imura H, Hamashima Y. Prevention of type I diabetes in nonobese diabetic mice by allogenic bone marrow transplantation. Proc Natl Acad Sci USA 1985; 82: 7743-7.
20. Adams AB, Durham MM, Kean L, Shirasugi N, Ha J, Williams MA, Rees PA, Cheung MC, Mittelstaedt S, Bingaman AW, Archer DR, Pearson TC, Waller EK, Larsen CP. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 2001; 167: 1103-11.
21. Durham MM, Bingaman AW, Adams AB, Ha J, Waitze SY, Pearson TC, Larsen CP. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165: 1-4.
22. Brodsky I, Bulova S, Crilley P. The role of busulfan/cyclophosphamide regimens in allogeneic and autologous bone marrow transplantation. Cancer Invest 1989; 7: 509-13.
23. Wekerle T, Kurtz J, Ito H, Ronquillo JV, Dong V, Zhao G, Shaffer J, Sayegh MH, Sykes M. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6: 464-9.
24. Adams AB, Shirasugi N, Jones TR, Williams MA, Durham MM, Ha J, Dong Y, Guo Z, Newell KA, Pearson TC, Larsen CP. Conventional immunosuppression is compatible with costimulation blockade-based, mixed chimerism tolerance induction. Am J Transplant 2003; 3: 895-901.
25. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168-70.
26. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989; 169: 493-502.
27. Markees TG, Philips NE, Gordon EJ, Noelle RJ, Shultz LD, Mordes JP, Greiner DL, Rossini AA. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4+ T cells, interferon V and CTLA4. J Clin Invest 1998; 101: 2446-55.
28. Tomita Y, Sachs DH, Sykes M. Myleosuppressive conditioning is required to achieve engraftment of pluripotent stem cells contained in moderate doses of syngeneic bone marrow. Blood 1994; 83: 939-48.
29. Shehee WR, Oliver P, Smithies O. Lethal thalassemia after insertional disruption of the mouse major adult β-globin gene. Proc Natl Acad Sci USA 1993; 90: 3177-81.
30. Dai Z, Konieczny BT, Baddoura FK, Lakkis FG. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J Immunol 1998; 161: 1659-63.
31. Ferrara JL, Marion A, McIntyre JF, Murphy GF, Burakoff SJ. Amelioration of acute graft vs host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody. J Immunol 1986; 137: 1874-7.
32. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431-40.
33. Kumanogoh A, Wang X, Lee I, Watanabe C, Kamanaka M, Shi W, Yoshida K, Sato T, Habu S, Itoh M, Sakaguchi N, Sakaguchi S, Kikutani H. Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. J Immunol 2001; 166: 353-60.
34. Suzuki K, Nakajima H, Saito Y, Saito T, Leonard WJ, Iwamoto I. Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice. Int Immunol 2000; 12: 123-32.